<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03146637</url>
  </required_header>
  <id_info>
    <org_study_id>BK2016.01</org_study_id>
    <nct_id>NCT03146637</nct_id>
  </id_info>
  <brief_title>Study of Activated CIK Armed With Bispecific Antibody for Advanced Liver Cancer</brief_title>
  <official_title>Phase II Randomized Comparison Clinical Trial of Target Activated CIK for Advanced Liver Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing 302 Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II Randomized comparison clinical trial of activated CIK armed with&#xD;
      anti-CD3-MUC1/CEA/EpCAM/GPC3 bispecific antibody for advanced liver cancer. And the aim of&#xD;
      this research is to study the clinical efficacy and safety of activated CIK armed with&#xD;
      anti-CD3-MUC1/CEA/EpCAM/GPC3 bispecific antibody for liver cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Liver cancer is one of the most common malignancies in China, ranking fourth in all malignant&#xD;
      tumors and third in mortality. Immunetherapy is considered to be one of the most promising&#xD;
      means of human against cancer. This is a phase II clinical trial of single-center, randomized&#xD;
      (1:1of targeted activation CIK and traditional CIK therapy )comparison clinical trial of&#xD;
      activated CIK armed with anti-CD3-MUC1/CEA/EpCAM/GPC3 bispecific antibody for advanced liver&#xD;
      cancer. The investigators plan to recruit for 80 cases patients with advanced liver cancer,&#xD;
      the first 20 cases were directly received treatment of activated CIK, and the cases after the&#xD;
      20th were randomly assigned to two group，one of the two group will receive treatment of&#xD;
      traditional CIK, and the other receive activated CIK. The result of this study was statistic&#xD;
      and analysed with the record of Response Evaluation Criteria In Solid Tumors(RECIST1.1)&#xD;
      evaluation standard.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2017</start_date>
  <completion_date type="Anticipated">January 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 27, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a phase II clinical trial of single-center, randomized (1:1of targeted activation CIK and traditional CIK therapy ).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>With the method of minimum randomized dynamic random by the interactive network response system (IWRS),Participants were randomly assigned to two groups,receive activated CIK or activated CIK armed with anti-CD3-MUC1/CEA/EpCAM/GPC3 bispecific antibody,every participant has a unique identification number and emergency letter which have the information of group.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>OS</measure>
    <time_frame>3 years</time_frame>
    <description>Overrall survival.The time of patient from randomization to death caused by any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>3 years</time_frame>
    <description>Progression-free survival.The time of patients from randomization to death caused by the progression of the tumor or any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTP</measure>
    <time_frame>1 years</time_frame>
    <description>Time tumor progression.The time of patient from randomization to objective progress of the tumor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>1 years</time_frame>
    <description>Disease control rate.The proportion of patients who had a best response rating of complete response, partial response, or stable disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>1 years</time_frame>
    <description>Objective response rate.The proportion of patients who had a best response rating of complete response and partial response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SRR</measure>
    <time_frame>1 years</time_frame>
    <description>Symptom remission rate. The proportion of symptoms are alleviated in all evaluative cases.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Advanced Liver Cancer</condition>
  <arm_group>
    <arm_group_label>Activated CIK armed with bispecific antibody treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CIK cells were activated by bispecific antibody of anti-CD3-MUC1/CEA/EpCAM/GPC3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Traditional CIK treatment group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CIK cells were not activated</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Activated CIK</intervention_name>
    <description>Activated CIK armed with bispecific antibody were infused for 3 days，after 2 days，bispecific antibody was infused separately for 3 days</description>
    <arm_group_label>Activated CIK armed with bispecific antibody treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CIK</intervention_name>
    <description>Traditional CIK were infused for 3 days</description>
    <arm_group_label>Traditional CIK treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18-75 years old;&#xD;
&#xD;
          2. The patient is diagnosed as advanced liver cancer,MUC1/CEA/EpCAM/GPC3 is positive;&#xD;
&#xD;
          3. There is at least one tumor should be measured,and length≥10mm of focus not at lymph&#xD;
             node or length≥10mm of focus at lymph node;&#xD;
&#xD;
          4. C interval of BCLC;&#xD;
&#xD;
          5. The patient can't tolerate system(systemic chemotherapy/molecular targeted therapy) or&#xD;
             local therapies;&#xD;
&#xD;
          6. Child-Pugh Score ≤7;&#xD;
&#xD;
          7. If the patient received adjuvant chemotherapy after local treatment,the time should be&#xD;
             more than 4 weeks after the end of chemotherapy, and disease progression or metastasis&#xD;
             patients can also assigned into the group;&#xD;
&#xD;
          8. The time of surgical treatment≥ 3 months ;At the end of the intervention, radiotherapy&#xD;
             and the end of the ablation time is more than 4 weeks;&#xD;
&#xD;
          9. The expected survival time ≥4 months；&#xD;
&#xD;
         10. The patient did not took any antitumor drugs within two weeks(any antitumor drugs,&#xD;
             Chinese patent medicine including Delisheng injection, Kanglaite injection, Aidi&#xD;
             injection, huaier granule and Ganfule Pian);&#xD;
&#xD;
         11. ECOG Score ≤1；&#xD;
&#xD;
         12. HBV DNA&lt;10^4copies/ml（2000IU/ml);&#xD;
&#xD;
         13. Serum albumin≥28g/L,ALT and AST≤5.0×ULN,TBIL≤1.5×ULN, electrolyte is normal,&#xD;
             proteinuria = 0 ~ 1 +, serum creatinine≤1.5 x ULN;&#xD;
&#xD;
         14. Tests of blood,liver and kidney should meet the following&#xD;
             criteria:WBC≥3×10^9/L,NEUT≥1×10^9/L,Hemoglobin ≥90 g/L,ANC≥1.5×109/L,PLT≥50×10^9/L;&#xD;
&#xD;
         15. No serious disease are conflicts with the solution(such as autoimmune&#xD;
             disease,immunodeficiency,orgen transplantation);&#xD;
&#xD;
         16. Sign the informed consent;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe cirrhosis, medium or above ascites;&#xD;
&#xD;
          2. Cancer embolus in the main portal vein and first branch, Hepatic duct and first&#xD;
             branch, hepatic vein, inferior vena cava;;&#xD;
&#xD;
          3. Patients of T cell lymphoma、myeloma,and patients are using immunosuppressant;&#xD;
&#xD;
          4. Systemic autoimmune diseases, allergic constitution or immunocompromised patients.&#xD;
&#xD;
          5. Patients of chronic diseases need immune stimulant or hormone therapy ;&#xD;
&#xD;
          6. Patients of active bleeding or coagulant function&#xD;
             abnormality（PT&gt;16s、APTT&gt;43s、TT&gt;21s、INR≥2）,and patients of bleeding tendency or are&#xD;
             receiving thrombolysis and anticoagulation and antiplatelet therapy;&#xD;
&#xD;
          7. Women who is pregnant or during breast feeding or plan to pregnant in 2 years,and not&#xD;
             willing to contraception during the test;&#xD;
&#xD;
          8. Any significant clinical and laboratory abnormalities, the researchers think that&#xD;
             affect the safety, such as: incontrollable active infection (&gt; NCI - CTC AE v4.0&#xD;
             standard level 2), uncontrolled diabetes (&gt; level 2 of NCI - CTC AE v4.0 ),&#xD;
             hypertension and can't be controlled by two or less hypotensor(systolic pressure &lt; 140&#xD;
             mmHg, diastolic pressure &lt; 90 mmHg), grade II or above peripheral neuropathy (NCI CTC&#xD;
             AE v4.0), grade II or above congestive heart failure (NCI CTC AE v4.0), myocardial&#xD;
             infarction in 6 month, thyroid dysfunction (&gt; level 2 of NCI - CTC AE v4.0), etc;&#xD;
&#xD;
          9. Patients with brain、dura mater metastases or history of psychogeny;&#xD;
&#xD;
         10. Gastrointestinal bleeding in the past six months or have clear gastrointestinal&#xD;
             bleeding tendency,such as: patients of local active ulcerative lesions, defecate&#xD;
             occult blood + + above shall not enter into group; defecate occult blood + depend on&#xD;
             gastroscopy;&#xD;
&#xD;
         11. Patients with severe stomach/esophageal varices and need for intervention treatment;&#xD;
&#xD;
         12. Patients with abdominal fistula, gastrointestinal perforation or abdominal abscess&#xD;
             within 4 weeks before the first treatment;&#xD;
&#xD;
         13. Patients with glomenrular filtration rate abnormal obviously(The endogenous creatinine&#xD;
             clearance &lt; 60 ml/min or serum creatinine &gt; 1.5 x ULN);&#xD;
&#xD;
         14. Positive for HIV antibody;&#xD;
&#xD;
         15. Patients who are allergic to computed tomography (CT) and magnetic resonance imaging&#xD;
             (MRI) contrast agents at the same time, can't imaging assay;&#xD;
&#xD;
         16. Patients accepted any experimental drugs or pilot medical apparatus and instruments in&#xD;
             the past 4 weeks of first treatment;&#xD;
&#xD;
         17. Other reasons the researchers think not suitable.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yinying Lu, Doctor</last_name>
    <role>Study Director</role>
    <affiliation>Liver Cancer Diagnosis &amp; Treatment and Research Center of 302 Military Hospital of China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiamin Cheng, Doctor</last_name>
    <phone>+86-10-66933129</phone>
    <phone_ext>6030</phone_ext>
    <email>chengjiamin300@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>302 Military Hospital of China</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100039</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiamin Cheng, Doctor</last_name>
      <phone>+86-10-66933129</phone>
      <phone_ext>6030</phone_ext>
      <email>chengjiamin300@163.com</email>
    </contact>
    <investigator>
      <last_name>Yinying Lu</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhen Zeng</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xuechun Lu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jiamin Cheng</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhengcheng Li</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jun Hou</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ting Zhang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chunping Wang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guanghua Rong</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bin Yang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yan Chen</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ze Liu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>May 2, 2017</study_first_submitted>
  <study_first_submitted_qc>May 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2017</study_first_posted>
  <last_update_submitted>January 27, 2021</last_update_submitted>
  <last_update_submitted_qc>January 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Activated CIK</keyword>
  <keyword>MUC1/CEA/EpCAM/GPC3</keyword>
  <keyword>Bispecfic antibody</keyword>
  <keyword>liver cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>When the study is finished</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

